Serial measurement of free light chain detects poor response to therapy early in three patients with multiple myeloma who have measurable M-proteins

International Journal of Hematology

Volumn 96, Issue 5, 2012, Pages 664-668

  Fuchida, Shin Ichi ^a   Okano, Akira ^a   Hatsuse, Mayumi ^a   Murakami, Satoshi ^a   Haruyama, Harue ^a   Itoh, Saori ^b   Shimazaki, Chihiro ^a  

^a Social Insurance Kyoto Hospital   (Japan)

^b Medical & Biological Laboratories Co Ltd   (Japan)

Author keywords

Chemotherapy; Free light chain; Multiple myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; FREE LIGHT CHAIN PROTEIN; M PROTEIN; PARAPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DRUG MEGADOSE; FEMALE; FREE LIGHT CHAIN ASSAY; HUMAN; HUMAN CELL; IMMUNOASSAY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PLASMA CELL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES;

EID: 84872173969     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1164-0     Document Type: Article

References (8)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004; 351:1860-73.
2. Shaw GR. Nonsecretory plasma cell myeloma-becoming even more rare with serum free light-chain assay. Arch Pathol Lab Med. 2006;130:1212-5.
3. Durie BGM, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Abderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-73.
4. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DE, Therneau TM, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008;22:1933-7.
5. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood. 2008;111:4908-15.
6. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110: 827-32.
7. Mori S, Crawford BS, Roddy JV, Phillips G, Elder P, Hofmeister CC, et al. Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents. Hematol Oncol. 2011 (Epub ahead of print)..
8. Dogaru M, Lazar V, Coriu D. Assessing the efficiency of free light chain assay in monitoring patient with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation. Roum Arch Microbiol Immunol. 2011;70:15-22.